-
2
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
3
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006:24: 4293-4300.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4293-4300
-
-
Abou-Alfa, G.K.1
Schwartz, L.2
Ricci, S.3
-
4
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378 -390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
5
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
6
-
-
28844490547
-
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
-
D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44:217-231.
-
(2006)
J Hepatol
, vol.44
, pp. 217-231
-
-
D'Amico, G.1
Garcia-Tsao, G.2
Pagliaro, L.3
-
7
-
-
59149096464
-
Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?
-
217s
-
Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008;26:(15 suppl):217s.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 SUPPL.
-
-
Abou-Alfa, G.K.1
Amadori, D.2
Santoro, A.3
-
8
-
-
58049217937
-
Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients
-
656s
-
Yau T, Chan P, Ng K et al. Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients. J Clin Oncol 2008;26:(15 suppl):656s.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 SUPPL.
-
-
Yau, T.1
Chan, P.2
Ng, K.3
-
9
-
-
61449256583
-
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis
-
Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. The Oncologist 2009;14:70-76.
-
(2009)
The Oncologist
, vol.14
, pp. 70-76
-
-
Pinter, M.1
Sieghart, W.2
Graziadei, I.3
-
10
-
-
61449095992
-
-
Nexavar®tablets (Bayer HealthCare Pharmaceuticals). In: 2009 Physician's Desk Reference (PDR), 63rd Edition. Toronto, Canada: Thomson, 2009:784-790.
-
Nexavar®tablets (Bayer HealthCare Pharmaceuticals). In: 2009 Physician's Desk Reference (PDR), 63rd Edition. Toronto, Canada: Thomson, 2009:784-790.
-
-
-
-
11
-
-
33645648696
-
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
-
Lathia C, Lettieri J, Cihon F et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-692.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 685-692
-
-
Lathia, C.1
Lettieri, J.2
Cihon, F.3
-
12
-
-
38049019119
-
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials
-
Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-548.
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 535-548
-
-
Takimoto, C.H.1
Awada, A.2
-
13
-
-
38049021509
-
Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301
-
147s
-
Miller AA, Murry DJ, Owzar K et al. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J Clin Oncol 2007;25(18 suppl):147s.
-
(2007)
J Clin Oncol
, vol.25
, Issue.18 SUPPL.
-
-
Miller, A.A.1
Murry, D.J.2
Owzar, K.3
-
14
-
-
36949033865
-
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
-
Furuse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sei 2008;99:159-165.
-
(2008)
Cancer Sei
, vol.99
, pp. 159-165
-
-
Furuse, J.1
Ishii, H.2
Nakachi, K.3
|